NOV 09, 2017 7:30 AM PST

Keynote Presentation: Integration of the Simplexa C. difficile Direct assay into a two-step algorithm for the laboratory diagnosis of C. difficile

  • Professor of Pathology and Laboratory Medicine, University of Louisville
      Dr. Snyder is the Medical Director of the Clinical Microbiology & Molecular Diagnostics Laboratory at the University of Louisville Hospital, and Professor of Pathology and Laboratory Medicine in the Department of Pathology and Laboratory Medicine at the University of Louisville, School of Medicine.

      He has been a part of ASM for many years. He currently serves on the Editorial Board for the Journal of Clinical Microbiology, is a member of the APHL Biosafety/Biosecurity Committee, and a past member of the APHL Sentinel Laboratory Partners Outreach Committee. He is also currently a member of the South Central Association for Clinical Microbiology Audioconference Planning Committee and President Elect of SCACM.

      He has authored or co-authored over 60 publications and was the recipient of the TREK Diagnostic ABMM/ABMLI Professional Recognition Award at ASM in 2009.


    Clostridium difficile infection (CDI) has become the leading cause of healthcare associated infections in the United States and currently accounts for 15% to 20% of infectious diarrhea in the healthcare setting.  Accurate diagnosis of CDI is criticalin promoting effective management of patients and implementing appropriate infection control measures to disrupt and prevent transmission.  Reliable diagnostic tests are needed to confirm or negative a presumptive clinical diagnosis of CDI.  Nucleic acid amplification tests (NAAT) have become available within the last ten years and have been used in one of two ways: 1) Direct testing, 2) algorithmic testing as a supplement to enzyme immunoassay (EIA) for the detection of glutamate dehydrogenase and Toxin A/B.  Much controversy exists as to which approach, direct NAAT or algorimthic is optimal for the laboratory diagnosis of CDI.  The latest NAAT-based test to enter the market is the Simplexa C. diffcile Direct Assay,   An evaluation of this technology was conducted for the purpose of determining its overall performance and potential integration into two-step algorithm testing format.  The assay was evaluated and compared to two other NAAT platforms.  The results of this evaluation are the subject of this presentation.

    Show Resources
    Show Resources
    • See more